<DOC>
	<DOCNO>NCT00965731</DOCNO>
	<brief_summary>This Phase 1/2 study compare safety anti-tumor activity erlotinib alone versus erlotinib combination PF-02341066 patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Erlotinib Is Being Studied With Or Without An Investigational Drug , PF-02341066 , In Patients With Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>histologically proven diagnosis NonSmall Cell Lung Cancer ( NSCLC ) locally advanced metastatic adenocarcinoma subtype ( include mixed adenosquamous histology ) evident disease progression Response Evaluation Criterion Solid Tumors ( RECIST ) least one 2 chemotherapy regimen advance disease tumor must measurable disease per RECIST know interstitial lung disease prior treatment agent know propose active action EGFR tyrosine kinase cMet/HGF ( Phase 2 Portion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Crizotinib</keyword>
</DOC>